17 apr: FOCUS: Food Processors To Benefit From Cheaper Grain Prices
17 apr: UPDATE: Marathon Oil: Angola's Block 31 To Start Product..
17-04-2012 21:04:00

2nd UPDATE:Top Court Sides With Generic Drug Makers In Tactics Case

Relateret indhold
25 nov - 
Novo: Victoza-rival får grønt lys i Europa
25 nov - 
Aktier/åbning: FLSmidth tager førerpositionen
25 nov - 
Aktier/tendens: Rockwool skal møde analytikerne

--Justices give generics new legal tool against brand rivals

--Sun unit wins case, calls ruling important for generic drug makers

--Case involved Novo Nordisk patent for diabetes drug Prandin

(Updates with comment from Novo in 12th paragraph, additional background.)

By Brent Kendall

Of DOW JONES NEWSWIRES

WASHINGTON -(Dow Jones)- The U.S. Supreme Court handed a victory to generic drug companies Tuesday, ruling they can file certain legal counterclaims against brand-drug companies in an effort to get their cheaper copycat medicines on the market.

The court, in an opinion written by Justice Elena Kagan, ruled unanimously that generic drug makers should be allowed to challenge the way brand-name manufacturers describe their patents to the Food and Drug Administration.

The decision overturned an appeals court ruling that said generic makers can't bring those legal claims against brand rivals.

The generics argued that their brand rivals, if left unchecked, can describe their patents broadly in FDA submissions as a way to shut out possible generic competition, even for unpatented uses of a drug. The Obama administration supported those arguments.

Brand drug companies said allowing the counterclaims could lead to costly litigation and undermine patent protection for innovative drugs that are costly to develop.

The controversy arises when the FDA considers a drug maker's application to market a generic drug. As part of that process, the agency considers whether the proposed generic will infringe a branded drug's patents. To determine infringement, the FDA relies on use codes submitted by brand companies that describe the scope of their patents. The agency does not independently verify the accuracy of companies' patent submissions.

As Kagan noted, "the breadth of the use code may make the difference between approval and denial of a generic company's application."

At issue was an appeal by Caraco Pharmaceutical Laboratories, a unit of Sun Pharmaceutical Industries Ltd. (524715.BY), which is seeking to introduce a generic version of Novo Nordisk A/S's (NVO, NOVO-B.KO) diabetes drug Prandin.

One Novo Nordisk patent on the drug compound has expired, but the company holds a second patent, which doesn't expire until 2018, that involves the use of the drug in combination with another medicine.

The FDA has approved three uses for the drug. Caraco wants to introduce a generic version for the uses that aren't patented. The company said it couldn't do so because Novo Nordisk's description of its patent to the FDA was so broad that it foreclosed the agency from approving a generic version of the drug.

A Sun representative called Tuesday's ruling "a very important victory" for the company and the generic industry as a whole.

Novo said its FDA submission is correct. "We are confident that further proceedings will show Caraco's challenge to the use code narrative is meritless," James Shehan, general counsel of Novo's U.S. subsidiary, said in a statement.

In a related dispute, the two companies are fighting over the validity of the Novo patent, which a Michigan federal judge invalidated last year. That case is on appeal.

The case is Caraco Pharmaceutical Laboratories v. Novo Nordisk, 10-844.

-By Brent Kendall, Dow Jones Newswires; 202-862-9222; brent.kendall@dowjones.com

(END) Dow Jones Newswires

April 17, 2012 15:04 ET (19:04 GMT)

Copyright (c) 2012 Dow Jones & Company, Inc.

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
22 nov
NOVO-B
'Vrøvl' "Novo sælger man ikke men giver videre til sine børnebørn" (det var i gamle dage)   Novo tra..
4
23 nov
NOVO-B
Det er utroligt at se de gamle garvede hoppe i med begge ben og sidder og ikke kan enes, fordi den e..
3
22 nov
NOVO-B
2 på hinanden højere bunde og toppe - og nedtrend omvendt   bliver af mange brugt som retningsindika..
3
25 nov
NOVO-B
nej, når kemikalier bliver forbudte, og det gør de alle som en, og olien bliver erstattet med ren en..
2
22 nov
NOVO-B
Novo er en gudeaktie   Som andre har sagt. Novo køber man og beholder til man vil købe en caribisk Ø..
2
22 nov
NOVO-B
Det er rigtigt at Novo er tæt på ATH, men de er absolut ikke i nedtrend.Køb og behold er budet fra m..
2
25 nov
NOVO-B
samme sag med novo ;O)) medicin slår folk ihjel... så det er også kun et spørgsmål om tid... også sh..
1
23 nov
NOVO-B
NNIT sælges for 8 Milliarder. Penge som så skal bruges til at købe Fedme fabrikker/produkter for . N..
1
22 nov
NOVO-B
Det var dig de beskyldt mig for flere navne hvilket er latterligt, en anden debatør kom så med samme..
1
22 nov
NOVO-B
Du kontakter da bare EI og beder dem tjekke min IP-adresse op imod alle andre IP-adresser her på for..
1

Fondsbørsmeddelelser

Vestas-kunde reducerer havvindmølleprojekt

25-11-2014 15:09:17
Det tyske energiselskab E.On har skåret sin planer for havvindmølleparken Rampion på den britiske sydkyst til, så der nu planlægges med en kapacitet på 400 MW i..

Pandora-forhandler opjusterer forventningerne - NY

25-11-2014 14:05:07
Den amerikanske juvelerkæde Signet Jewelers, der blandt andet forhandler Pandora-smykker i USA, opjusterer i regnskabet for tredje kvartal af regnskabsåret 2014..

Novo: Victoza-rival får grønt lys i Europa

25-11-2014 10:15:30
Novo Nordisk kan nu også se frem til øget konkurrence til sit storsælgende diabetesmiddel Victoza på det det europæiske marked.Den amerikanske medicinalvirksomh..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge
1
Coca-Cola-mælk skal få det til at regne med penge - avis
2
Juncker klar med gigantisk redningsprogram - avis
3
Vestas-kunde reducerer havvindmølleprojekt
4
Novo: Victoza-rival får grønt lys i Europa
5
Carnegie i forklaringsproblem efter OW-aktiesalg - avis

Relaterede aktiekurser

Novo-Nordisk A/S 44,67 0,5% Stigning i aktiekurs
Novo Nordisk B A/S 266,50 0,0% Aktiekurs uændret
Euroinvestor i andre lande: Euroinvestor.com | Euroinvestor.se | Euroinvestor.no | Euroinvestor.fr | Forexinvestor.com| Wisselkoersen.nl | Valuta.se | Valutaveksel.no | Divisas.es | Valute.it
Copyright Euroinvestor A/S 2014  Disclaimer Privatlivspolitik
Aktieinformation leveres af Interactive Data.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
26. november 2014 05:03:17
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20141125.1 - EUROWEB5 - 2014-11-26 05:03:17 - 2014-11-26 05:03:17 - 1 - Website: OKAY

Når du besøger Euroinvestor.dk accepterer du, at der anvendes cookies, som vi og vores samarbejdspartnere benytter til funktionalitet, statistik og markedsføring. Læs mere om cookies på Euroinvestor.dk her

x